Prevalence of human papillomavirus, *Chlamydia trachomatis*, and *Trichomonas vaginalis* infections in Amazonian women with normal and abnormal cytology

E. Costa-Lira¹,³, A.H.V. Jacinto², L.M. Silva¹, P.F.R. Napoleão¹, R.A.A. Barbosa-Filho¹, G.J.S. Cruz³, S. Astolfi-Filho⁴ and C.M. Borborema-Santos³

¹Programa de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas, Manaus, AM, Brasil
²Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Amazonas, Manaus, AM, Brasil
³Laboratório de Diagnóstico Molecular, Centro de Apoio Multidisciplinar, Universidade Federal do Amazonas, Manaus, AM, Brasil
⁴Laboratório Tecnologias do DNA, Centro de Apoio Multidisciplinar, Universidade Federal do Amazonas, Manaus, AM, Brasil
⁵Departamento de Planejamento, Secretaria Municipal de Saúde de Manaus, Manaus, AM, Brasil

Corresponding author: E. Costa-Lira
E-mail: costa_eve@yahoo.com.br

Genet. Mol. Res. 16 (2): gmr16029626
Received January 25, 2017
Accepted March 13, 2017
Published April 28, 2017
DOI http://dx.doi.org/10.4238/gmr16029626

Copyright © 2017 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-SA) 4.0 License.

**ABSTRACT.** Sexually transmitted infections are an important cause of morbidity among sexually active women worldwide, and have been implicated as cofactors in the pathogenesis of cervical cancer. We investigated the prevalence of human papillomavirus (HPV), *Chlamydia trachomatis* (CT), and *Trichomonas vaginalis* (TV), and
accessed the diversity of HPV in women with normal and abnormal cytology in Manaus, Brazil. We used polymerase chain reaction and HPV genotyping by direct sequencing. The chi-square test was used to calculate the absolute and relative frequencies of the categorical variables, and Fisher’s test was used when P < 0.05. The level of significance was set at 5%. All statistical analyses were performed using R 2.9.0. There were statistically significant differences in age (P = 0.0395), education level (P = 0.0131), sexual partners (P = 0.0211), condom use (P = 0.0039), marital status (P < 0.0001), and pregnancy (P = 0.0003) between the normal and abnormal groups. HPV DNA was found in 36.56 and 93.88% of subjects in the normal and abnormal groups, respectively. A total of 19 genotypes were detected; HPV16 was the most common, followed by HPV58. The percentages of TV and CT DNA were 18.04 and 9.02% in the normal group, respectively. The percentages of HPV/TV and HPV/CT coinfection were 12.5% each in women with normal cytology. These findings improve our understanding of HPV, CT, and TV, and the distribution of HPV types, which may be relevant to vaccination strategies for protecting women from the north of Brazil from cervical cancers and precancerous lesions.

**Key words:** Human papillomavirus; *Chlamydia trachomatis*; *Trichomonas vaginalis*; Polymerase chain reaction; Prevalence

**INTRODUCTION**

Cervical cancer is the second most common cancer in women in developed countries, and it is estimated that there are 530,000 new cases each year [WHO (World Health Organization), 2016]. In Brazil, it is estimated that there were 16,340 new cases in 2016, with a risk factor of 15 cases per 100,000 women. Excluding non-melanoma skin tumors, cervical cancer is the most prevalent cancer in the north region of Brazil, unlike in other Brazilian regions, with an incidence of 23.97/100,000 women [INCA (Instituto Nacional de Câncer José Alencar Gomes da Silva), 2015]. Persistent infection with human papillomavirus (HPV) is the principal cause of cervical cancer and its precursor, cervical intraepithelial neoplasia.

According to their oncogenic potential, the different types of HPV are classified as low-risk viruses (LR-HPV: 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and 89), high-risk viruses (HR-HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), and probably high-risk viruses (pHR-HPV: 26, 53, and 66) (de Villiers et al., 2004; Muñoz et al., 2006). Both oncogenic and non-oncogenic types of HPV can cause low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), and may or may not lead to the development of cervical cancer. HPV16 and 18, however, are responsible for 50 and 20% of all cases of cervical cancer worldwide, respectively (Burk et al., 2009). Although they are very common among young women, the majority of HPV infections are transient, and only a small percentage of women develop a persistent infection (Giuliani et al., 2006).

According to World Health Organization (WHO, 2016), more than one million sexually transmitted infections (STIs) are acquired every day. Every year, approximately 357 million new infections of *Chlamydia trachomatis* (CT) and *Trichomonas vaginalis* (TV),
which are the most common causative agents of STIs, are reported. Pathogens that can be transmitted sexually have been implicated as cofactors in the pathogenesis of cervical cancer (WHO, 2008; INCA, 2015).

The objectives of this study were to investigate the prevalence of HPV, CT, and TV, and to access the diversity of HPV types. We used the polymerase chain reaction and HPV genotyping by direct sequencing in women with normal and abnormal cytology who used health services in Manaus, Amazonas, Brazil.

**MATERIAL AND METHODS**

**Study groups**

A total of 180 women who used public health services were recruited between October 2013 and April 2014 in Manaus, Amazonas, Brazil. Of those women, 133 were recruited from basic health units and 47 were recruited from the Amazon State Foundation Oncology Control Center (FCECON-AM), which is a reference hospital for cancer treatment in the city. The subjects presented with cytopathological, histopathological, and colposcopic indications of uterine cervical pathologies. All subjects were informed about the objectives, benefits, and risks of this study. Recruitment was by invitation and the subjects were required to answer a socio-economic-cultural questionnaire. Informed consent was obtained from all participants. The study was approved by the Human Research Ethics Committee of the Federal University of Amazonas (CAAE No. 12240113.8.0000.5020).

**Sample collection and DNA extraction**

Cervical samples were collected using a cytobrush and re-suspended in a 1.5-mL microtube containing 400 μL TE buffer comprising 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA. They were then immediately transported on ice to the Laboratory of Molecular Diagnosis in the Federal University of Amazonas (UFAM), and stored at -80°C until required.

DNA was extracted from the cervical samples using a QIAamp® DNA Mini Kit (Qiagen, Brazil) following the manufacturer instructions. DNA concentrations were estimated using a BioPhotometer D30 spectrophotometer (Eppendorf, Brazil) by measuring the absorbance at 260 and 280 nm. The samples were then stored at -20°C until required for further processing.

**Polymerase chain reaction (PCR) for HPV DNA detection and genotyping**

HPV detection was carried out using nested-PCR (nPCR). The first reaction was performed using MY09/MY11 primers (Manos et al., 1989) to amplify a 450-bp fragment. The final volume of the reaction mixture was 25 μL, comprising 2.5 μL DNA, 2.5 μL 10X reaction buffer, 0.8 μL 50 mM MgCl₂, 0.5 μL 10 mM dNTP, 2.5 μL each primer (5 pmol/μL), 0.1 μL 5U/μL Platinum® Taq DNA Polymerase (Invitrogen, Brazil), and 13.6 μL Milli-Q water.

The second reaction was performed using GP5+/GP6+ internal primers (Snijders et al., 1990), which amplified a 150-bp fragment. The final volume of the second reaction mixture was 25 μL, comprising the sample (1 μL), 2.5 μL 10X reaction buffer, 0.8 μL 50 mM MgCl₂, 0.5 μL 10 mM dNTP, 2.5 μL each primer (5 pmol/μL), 0.1 μL 5U/μL Platinum® Taq DNA Polymerase (Invitrogen, Brazil), and 15.1 μL Milli-Q water to complete the final volume.
conditions for both reactions were as follows: 95°C for 1 min; 40 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min; and a final extension for 5 min at 72°C.

The PCR products from all positive HPV DNA samples were purified using the ExoSap protocol (GE Healthcare, Brazil) and prepared for sequencing in a final volume of 10 µL, comprising the sample (2 µL), 0.5 µL BigDye™ Terminator, 2 µL 5X reaction buffer, 0.64 µL 5 pmol primers (MY09, MY11, GP5+, or GP6+), and 4.86 µL Milli-Q water. The reaction conditions were as follows: 94°C for 1 min; and 25 cycles of amplification at 96°C for 15 s, 50°C for 15 s, and 60°C for 4 min.

Sequencing was performed on an ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer recommendations. The sequences were edited and aligned using version 7.2.5 of BioEdit (Hall, 1999), and compared with the sequences included in the GenBank database.

**PCR for C. trachomatis DNA detection**

*C. trachomatis* PCR detection was performed using KL1/KL2 primers (Mahony et al., 1993) to amplify a 241-bp fragment of a plasmid DNA of *C. trachomatis*. The final reaction volume (25 µL) comprised 2.5 µL DNA, 2.5 µL 10X reaction buffer, 1 µL 50 mM MgSO₄, 0.5 µL 10 mM dNTP, 2.5 µL each primer (5 pmol/µL), 0.1 µL 5 U/µL Platinum® Taq DNA Polymerase (Invitrogen, Brazil), and 13.4 µL Milli-Q. The reaction conditions were as follows: 94°C for 30 s; 40 cycles of amplification at 94°C for 30 s, 64°C for 30 s, and 68°C for 2 min; and a final extension for 5 min at 68°C.

**PCR for T. vaginalis DNA detection**

The DNA of *T. vaginalis* was detected using a touchdown method, and BTUB9/BTUB2 primers (Madico et al., 1998) were used to amplify a 112-bp fragment of a beta-tubulin gene of *T. vaginalis*. The final volume of the reaction mixture was 25 µL, comprising 2 µL DNA, 2.5 µL 10X reaction buffer, 0.8 µL 50 mM MgCl₂, 0.5 µL 10 mM dNTP, 1 µL each primer (5 pmol/µL), 0.1 µL 5 U/µL Platinum® Taq DNA Polymerase (Invitrogen, Brazil), and 17.1 µL Milli-Q water. The reaction conditions were as follows: 95°C for 75 s; 60 cycles of denaturation at 95°C for 45 s; annealing starting at 62°C and ending at 52°C for 45 s; and extension at 72°C for 1 min. The annealing temperature was lowered by 1°C every four cycles until it reached 52°C, and this annealing temperature was then maintained until the end of the cycling process. All PCR reactions were performed in a Veriti thermocycler (Applied Biosystems, Foster City, CA). Water was included as a negative control, and a previously sequenced and tested sample was used as a positive control. The amplified products for the molecular diagnosis of HPV, *C. trachomatis*, and *T. vaginalis* were resolved by electrophoresis on 1.5% (MY09/MY11), 2.5% (GP5+/GP6+), 2% (KL1/KL2), and 2.5% (BTUB9/BTUB2) agarose gels containing ethidium bromide (0.5 mg/mL), and visualized with a transilluminator. The images were captured using an Olympus SP-500UZ digital camera.

**Statistical analysis**

We used the chi-square test to calculate the absolute and relative frequencies of the
categorical variables, whereas we used Fisher’s test when P values were less than 0.05. The mean and standard deviations were calculated for the quantitative variables using the Kruskal-Wallis test. The level of significance was set at 5%. All statistical analyses were performed using the R 2.9.0 software package.

RESULTS

We recruited 180 women who used the public health service. These women were divided according to cytopathological and histopathological findings. The normal group comprised 133 (73.88%) women who presented with inflammatory cytology, whereas the abnormal group comprised 23 (16.11%) with HSIL and 18 (10%) with LSIL. Table 1 shows the demographic, clinical, and molecular findings, and the relationship between the normal and abnormal status of the women in this study.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Abnormal cytology</th>
<th>Normal cytology</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16-20</td>
<td>2</td>
<td>21</td>
<td>0.0395</td>
</tr>
<tr>
<td>21-30</td>
<td>10</td>
<td>43</td>
<td>0.33</td>
</tr>
<tr>
<td>31-40</td>
<td>24</td>
<td>47</td>
<td>0.33</td>
</tr>
<tr>
<td>41-50</td>
<td>11</td>
<td>21</td>
<td>15.78</td>
</tr>
<tr>
<td>Education level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>21</td>
<td>29</td>
<td>21.59</td>
</tr>
<tr>
<td>High</td>
<td>22</td>
<td>77</td>
<td>56.38</td>
</tr>
<tr>
<td>Graduate</td>
<td>4</td>
<td>22</td>
<td>16.53</td>
</tr>
<tr>
<td>Age at first intercourse</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-15</td>
<td>20</td>
<td>55</td>
<td>41.35</td>
</tr>
<tr>
<td>16-20</td>
<td>25</td>
<td>60</td>
<td>45.11</td>
</tr>
<tr>
<td>21-30</td>
<td>2</td>
<td>12</td>
<td>9.02</td>
</tr>
<tr>
<td>Sexual partners</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>11</td>
<td>51</td>
<td>38.34</td>
</tr>
<tr>
<td>3-4</td>
<td>15</td>
<td>47</td>
<td>35.33</td>
</tr>
<tr>
<td>&gt;5</td>
<td>21</td>
<td>31</td>
<td>23.30</td>
</tr>
<tr>
<td>Condom use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>9</td>
<td>57</td>
<td>42.86</td>
</tr>
<tr>
<td>Yes</td>
<td>37</td>
<td>76</td>
<td>57.14</td>
</tr>
<tr>
<td>Sometimes</td>
<td>1</td>
<td>0</td>
<td>~0.0001</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1</td>
<td>57</td>
<td>42.85</td>
</tr>
<tr>
<td>Yes</td>
<td>32</td>
<td>75</td>
<td>56.38</td>
</tr>
<tr>
<td>Pregnancy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>3</td>
<td>27</td>
<td>20.30</td>
</tr>
<tr>
<td>Single</td>
<td>3</td>
<td>27</td>
<td>20.30</td>
</tr>
<tr>
<td>Double</td>
<td>7</td>
<td>30</td>
<td>22.55</td>
</tr>
<tr>
<td>Multiple (3-9)</td>
<td>34</td>
<td>49</td>
<td>36.84</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>32</td>
<td>93</td>
<td>69.92</td>
</tr>
<tr>
<td>Current</td>
<td>2</td>
<td>10</td>
<td>7.61</td>
</tr>
<tr>
<td>In the past</td>
<td>13</td>
<td>22</td>
<td>16.54</td>
</tr>
<tr>
<td>Presence of HPV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>3</td>
<td>85</td>
<td>63.90</td>
</tr>
<tr>
<td>Yes</td>
<td>44</td>
<td>48</td>
<td>36.09</td>
</tr>
<tr>
<td>Presence of CT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>47</td>
<td>123</td>
<td>90.97</td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>12</td>
<td>9.02</td>
</tr>
<tr>
<td>Presence of TV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>47</td>
<td>199</td>
<td>81.95</td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>24</td>
<td>18.05</td>
</tr>
</tbody>
</table>

HPV: human papillomavirus. CT: Chlamydia trachomatis. TV: Trichomonas vaginalis.
There were statistically significant differences in age (P = 0.0395), education level (P = 0.0131), number of sexual partners (P = 0.0211), condom use (P = 0.0039), marital status (P < 0.0001), and pregnancy (P = 0.0003) between the normal and abnormal groups. The percentages of HPV DNA were 36.56% (48/133) and 93.88% (46/49) in the normal and abnormal groups, respectively. The percentages of TV and CT DNA were 18.04% (24/133) and 9.02% (12/133) in the normal group, respectively.

Table 2 shows a total of 19 different HPV types were detected in this study: 7 HR, 6 LR, 3 pHR, and 3 undetermined risk (UR).

### Table 2. Distribution of human papillomavirus (HPV) genotypes and coinfections with *Trichomonas vaginalis* (TV) and *Chlamydia trachomatis* (CT).

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>Abnormal cytology</th>
<th>Normal cytology</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HPV</td>
<td>TV/HPV</td>
<td>CT/HPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>20</td>
<td>45.45</td>
<td>15</td>
<td>31.25</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>2.08</td>
<td>-</td>
</tr>
<tr>
<td>31</td>
<td>3</td>
<td>6.81</td>
<td>2</td>
<td>4.16</td>
<td>-</td>
</tr>
<tr>
<td>33</td>
<td>4</td>
<td>9.09</td>
<td>2</td>
<td>4.16</td>
<td>1</td>
</tr>
<tr>
<td>52</td>
<td>1</td>
<td>2.27</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>58</td>
<td>8</td>
<td>18.18</td>
<td>4</td>
<td>8.33</td>
<td>-</td>
</tr>
<tr>
<td>59</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>2.08</td>
<td>-</td>
</tr>
<tr>
<td>pHR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>2</td>
<td>4.34</td>
<td>3</td>
<td>6.25</td>
<td>-</td>
</tr>
<tr>
<td>66</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>4.16</td>
<td>1</td>
</tr>
<tr>
<td>82</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>2.08</td>
<td>-</td>
</tr>
<tr>
<td>LR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>2.27</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>54</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>2.08</td>
<td>-</td>
</tr>
<tr>
<td>61</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>6.25</td>
<td>-</td>
</tr>
<tr>
<td>70</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>6.25</td>
<td>1</td>
</tr>
<tr>
<td>72</td>
<td>1</td>
<td>2.27</td>
<td>1</td>
<td>2.08</td>
<td>-</td>
</tr>
<tr>
<td>81</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>4.16</td>
<td>-</td>
</tr>
<tr>
<td>UR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>2.08</td>
<td>1</td>
</tr>
<tr>
<td>83</td>
<td>1</td>
<td>2.27</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>102</td>
<td>1</td>
<td>2.27</td>
<td>1</td>
<td>2.08</td>
<td>1</td>
</tr>
<tr>
<td>Not identified</td>
<td>2</td>
<td>4.34</td>
<td>5</td>
<td>10.41</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>44</td>
<td>48</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

HR: high risk; pHR: probable high risk; LR: low risk; UR: undetermined risk.

The prevalence of HR HPV was 81.6% (36/44) in the abnormal group and 52.06% (25/48) in the normal group. HPV16 was seen as the most common type in women with abnormal cytology (20/44, 45.45%), followed by (in order of decreasing frequency): HPV58 (8/44, 18.18%); HPV33 (4/44, 9.09%); HPV31 (3/44, 6.81%); HPV53 (2/44, 4.54%); and HPV52, 6, 72, 83, and 102 (1/44, 2.27%). HPV16 was the most common type in the women, even with normal cytology (15/48, 31.25%), followed by (in order of decreasing frequency): HPV58 (8/48, 16.67%); HPV53, 61, and 70 (3/48, 6.25%); HPV31, 33, 66, and 81 (2/48, 4.16%); and HPV18, 59, 82, 54, 72, 62, and 102 (1/48, 2.08%). The percentages of HPV/TV and HPV/CT coinfections were both 12.5% (6/48).

Table 3 shows the HPV types found in the women with abnormal cytology. HPV DNA was detected in 93.61% (44/47) of women with abnormal cytology, in 36.36% (16/44) with LSIL, and 63.63% (28/44) with HSIL.
DISCUSSION

In the present study, we determined the prevalence of HPV, CT, and TV infections in women who attended public health services in Manaus, Amazonas, Brazil. We found a HPV detection rate of 36.09% in women with normal cytology and, as expected, 93.61% in women with premalignant and malignant cervical lesions. The prevalence of HPV in women with normal cytology was greater than the prevalence rates reported in the last ten years that range from 13 to 35% among women with normal cytology (Fedrizzi et al., 2008; Fernandes et al., 2009; Lippman et al., 2010; Oliveira et al., 2011; Castro et al., 2011; Rocha et al., 2014; Santos-Filho et al., 2016). Similarly, the rates of occurrence described for women with premalignant and malignant cervical lesions in the last 10 years were lower than those demonstrated in this study (de Paula et al., 2007; Paesi et al., 2009; Oliveira-Silva et al., 2011; Gurgel et al., 2013; Freitas et al., 2014). The most prevalent HR-HPV types were 16, 58, 33, and 31, both in the women with normal cytology and those with premalignant and malignant cervical lesions. The results corroborate the data described by Castro et al. (2011) and Rocha et al. (2014) for the State of Amazonia, which demonstrated high genotypic diversity. The prospective studies have shown that HPV-positive women are at higher risk of developing HSIL-like lesions than HPV-negative women (Khan et al., 2005). These risks increase with the presence of HPV types that are phylogenetically related to HPV16 and HPV18. Precancerous lesions can develop in women without any type of cytopathological abnormality up to two years after the detection of HPV16 or HPV18 DNA (Muñoz et al., 2006). Table 3 shows the types of HPV found in women with premalignant and malignant cervical lesions; in the majority of lesions, HSIL type 16 was present and no type 18 was detected in any of the groups. Although HPV infection is very common, less than 10% of women with an oncogenic type develop some kind of lesion, leading to the belief that the presence of HPV is necessary but not sufficient for the development of these lesions. Therefore, it is a risk cofactor. Among these subjects, there is prolonged use of oral contraceptives, multiparity, tabagism, a high number of sexual partners, and the presence of other STIs such as C. trachomatis, T. vaginalis, and HIV (Smith et al., 2004; INCA, 2015).

The current study showed an association between abnormal cytology and all risk factors related to sexual behavior, suggesting that these cofactors directly influence the development of lesions in HPV-positive women.

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>LSIL (N = 18)</th>
<th>HSIL (N = 29)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>HR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>6</td>
<td>33.33</td>
</tr>
<tr>
<td>31</td>
<td>2</td>
<td>11.11</td>
</tr>
<tr>
<td>33</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>52</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>58</td>
<td>4</td>
<td>22.22</td>
</tr>
<tr>
<td>pHR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>2</td>
<td>11.11</td>
</tr>
<tr>
<td>33</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>31</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>LR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>UR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>102</td>
<td>1</td>
<td>3.44</td>
</tr>
<tr>
<td>Not identified</td>
<td>1</td>
<td>5.55</td>
</tr>
<tr>
<td>No HPV detected</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>18</td>
<td>100</td>
</tr>
</tbody>
</table>

HR: high risk; pHR: probable high risk; LR: low risk; UR: undetermined risk; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion.
The prevalence of CT infections found in this study for women with normal cytology was 9.02%. This was lower than the rate described by Santos et al. (2003), which was 20.7% among sexually active women in the city of Manaus, AM, and higher than the prevalence described by Rocha et al. (2014), which was 6.4% among women seeking public health services in Coari, AM, Brazil. In a study in Manaus involving women with infertility correlated with CT, de Lima Freitas et al. (2011) observed a prevalence of 52.8%, which was much higher than that described by Fernandes et al. (2014), who reported a prevalence similar to our results (10.9%) among women with a history of infertility, who had undergone assisted reproduction techniques. Another important study carried out by Neves et al. (2016) on asymptomatic women aged 14-25 years who used public health services in Manaus showed a prevalence of 13.1% for CT infections, whereas in women aged 20-25 years this prevalence was 10.8%, as determined by the Digene Hybrid Capture II Test (HCII CT-ID). Our results corroborate the prevalence range found in the rest of Brazil (9.1-14.3%) (de Paula et al., 2007; Oliveira et al., 2009; Benzaken et al., 2010; Piazzetta et al., 2011; Garcês et al., 2013). CT infection is asymptomatic in almost all women and, if left untreated, can progress to complications such as ectopic pregnancy, pelvic inflammatory disease (PID), and tubal infertility (Golijow et al., 2005). Therefore, it is extremely important to track the pathogen in asymptomatic women to prevent future sequelae.

In this study, we found a prevalence of 18.04% for TV. This prevalence is higher than the prevalence (12.7%) described by Rocha et al. (2014) in a similar study performed in Coari, AM. In Brazil, studies that use molecular methods to investigate the prevalence of VT are scarce, which may be explained by the fact that notification of infection with the disease is not considered compulsory, as it is in many other countries (Hobbs and Seña, 2013). Furthermore, because it does not cause any serious sequelae, many clinicians considered it to be more of a nuisance rather than a public health threat. This makes the control of the disease even more difficult (Bowden and Garnett, 1999). The most important point regarding this pathogen is its association with the transmission of acquired human immunodeficiency virus (HIV), pelvic inflammatory disease (PID), infertility, preterm birth, low birth weight of infants born to infected mothers, and cervical cancer (CDC, 2015).

HPV/CT coinfection was found in 12.5% of the women participating in this study and, similarly, HPV/TV coinfection was noted in 12.5% women. HPV/CT/TV coinfection was found in 6.25% of the women, and this occurred in women infected with HPV of probable high risk, low risk, and undetermined risk (Table 2).

Thus, the results described in this study highlight the importance of the molecular diagnosis of HPV and of the sexually transmitted pathogens identified as possible cofactors for cervical oncogenesis, as well as the facilitators of other STIs including HIV. Moreover, the verification of the coinfection of these agents clarifies their role in the development of cervical cancer, and promotes the early diagnosis and subsequent treatment of women with these STIs. Information about the distribution of HPV types among women in different Brazilian regions is of paramount importance. This knowledge should be taken into account when considering the use of vaccines that confer protection from the various oncogenic types. At present in Brazil, the HPV vaccination campaign is targeting girls aged 9-13 years by using the quadrivalent HPV vaccine, which only provides immunization against HPV6, 11, 16, and 18. Recently, Joura et al. (2015) established the efficacy and immunogenicity of a nine-valent HPV vaccine that can protect against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 associated with cervical, vulvar, and vaginal cancer. Considering the prevalence of HR-HPV revealed by
this study (HPV16, 58, 33, and 31), we can infer that the nine-valent vaccine could also be a good option for protecting women from cervical cancers and precancer lesions.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

The authors are grateful to Edson de Freitas Gomes, Dr. Luiz Carlos dos Santos Júnior, Carla Virginia Lopes Machado, and Larissa de Souza Kirsch for sample collection and interviews, and Maria Ivanilde Silva Araújo, Enedina Nogueira D’Assunção, and Adolfo José da Mota for assisting in the statistical and sequencing analyses. Research supported in part by the Amazonas State Research Support Foundation (FAPEAM). URL: http://www.fapeam.am.gov.br.

REFERENCES


CDC (Centers for Disease Control and Prevention) (2015). Sexually Transmitted Diseases Treatment Guidelines. CDC, Atlanta.


Genetics and Molecular Research 16 (2): gmr16029626
